Adaptive Biotech Welcomes Chad Cohen As Its New Chief Financial Officer

SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, announced today the appointment of Chad Cohen as its new Chief Financial Officer, effective immediately. Mr. Cohen has served on Adaptive's Board of Directors since March 2015. Most recently, Mr. Cohen served as CFO for Zillow Group, where he oversaw all finance, treasury and accounting functions and led the finance organization through Zillow's 2011 IPO and nine acquisitions. Dean Schorno, Adaptive's preceding CFO, will step down to pursue a local opportunity in the San Francisco Bay Area where he resides.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.